IRB #

STUDY00020977

Title

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

Principal Investigator

Christopher Ryan

Study Purpose

The objective of this study is to if MK-6482 works better or worse than everiolimus in previously treated subjects with advanced or metastatic RCC.

Medical Condition(s)

Previously Treated Advanced Renal Cell Carcinoma

Eligibility Criteria

Age eighteen years or older on the day of consent with unresectable, locally advanced or metastatic clear cell RCC and has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology. Has received previous treatment for locally advanced or metastatic RCC with a PD-1/L1 checkpoint inhibitor.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until progression. Option to continue to receive study drug after progression as long as you are seeing clinical benefit.

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
Email: trials@ohsu.edu

Sponsor

Merck

Recruitment End

03/01/2022

Compensation Provided

No


Go Back